TREATMENT OF RESPIRATORY DISEASES
DE602016094074T2Active Publication Date: 2025-11-12TIANLI BIOTECH PTY LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DE602016094074
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2015-03-23
- Filing Date
- 2016-03-23
- Publication Date
- 2025-11-12
- Estimated Expiration
- 2036-03-23
AI Technical Summary
Technical Problem
There is a need for new and/or improved treatments or preventatives for pulmonary fibrosis, particularly in patients who have experienced or are experiencing resistance to treatment with glucocorticoids.
Method used
The use of an inhibitor of casein kinase 1, formulated as a dry powder for inhalation, to treat or prevent pulmonary fibrosis, optionally combined with glucocorticoids and other therapeutic agents.
Benefits of technology
The inhibitor of casein kinase 1 effectively reduces pulmonary fibrosis and alleviates symptoms by enhancing the effectiveness of glucocorticoid treatment, reducing inflammation, and preventing fibrotic progression.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.